Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

scientific article published on 22 May 2015

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1048024169
P356DOI10.1186/S13059-015-0657-6
P932PMC publication ID4440518
P698PubMed publication ID25994018
P5875ResearchGate publication ID277018168

P50authorJorge Reis-FilhoQ23892845
Paul M WilkersonQ114430433
Patty WaiQ114430434
Huei-Chi WenQ117222753
Rachael NatrajanQ30582887
Frédérique Penault-LlorcaQ30728827
Luciano G. MartelottoQ48118380
Charlotte K Y NgQ52733272
Raymond LimQ57152271
Britta WeigeltQ71780641
Felipe C GeyerQ89462283
Arnaud GauthierQ103831905
Larry NortonQ37644083
Salvatore PiscuoglioQ41195760
Anne Vincent-SalomonQ41605826
Xavier Sastre-GarauQ41607337
Magali Lacroix-TrikiQ41608027
P2093author name stringFrederique Penault-Llorca
Laurent Arnould
Paul H Cottu
Sylvia Giard
Daniel N Rodrigues
Catherine F Cowell
Silvio E Bromberg
P2860cites workZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epitheliumQ24293658
FAM83A confers EGFR-TKI resistance in breast cancer cells and in miceQ24296333
Intratumor heterogeneity: evolution through space and timeQ24598678
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenograftsQ24621116
Comprehensive molecular portraits of human breast tumoursQ24630844
A census of human cancer genesQ24647081
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityQ27006811
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerQ27824847
Activating HER2 mutations in HER2 gene amplification negative breast cancerQ27851987
Activating ESR1 mutations in hormone-resistant metastatic breast cancerQ27852630
ESR1 ligand-binding domain mutations in hormone-resistant breast cancerQ27852637
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneQ27860693
RCP is a human breast cancer-promoting gene with Ras-activating functionQ28252569
Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancerQ28279694
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-upQ28306437
Tumour evolution inferred by single-cell sequencingQ28646966
Inferring tumor progression from genomic heterogeneityQ28749457
The life history of 21 breast cancersQ29614642
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsQ29614700
Fibroblast growth factor signalling: from development to cancerQ29616827
The clonal and mutational evolution spectrum of primary triple-negative breast cancersQ29619914
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.Q30459163
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerQ30494798
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Q30543788
Resolving the resolution of array CGH.Q33271882
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breastQ33579776
Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinomaQ33644421
Clonal evolution in breast cancer revealed by single nucleus genome sequencing.Q34041603
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomasQ34094563
Functional genomics reveal that the serine synthesis pathway is essential in breast cancerQ34200610
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancerQ46755338
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateQ57130157
Intratumoral heterogeneity of HER2/neu in breast cancer--a rare eventQ79825280
Prognosis and gene expression profiling of 20q13-amplified breast cancersQ80087862
Insights from transgenic mouse models of ERBB2-induced breast cancerQ80188238
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platformsQ81290124
Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancerQ34216744
Absolute quantification of somatic DNA alterations in human cancerQ34271693
Spatial and temporal diversity in genomic instability processes defines lung cancer evolutionQ34442770
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisQ34493341
The Mub1/Ubr2 ubiquitin ligase complex regulates the conserved Dsn1 kinetochore proteinQ34585694
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutationsQ34663070
Transforming Properties of 8p11-12 Amplified Genes in Human Breast CancerQ34950377
Modelling glandular epithelial cancers in three-dimensional culturesQ36251934
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic diseaseQ36615272
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activityQ36732343
Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer researchQ36844700
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effortQ37006537
CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancerQ37121911
Immunophenotypic and genomic characterization of papillary carcinomas of the breastQ37130628
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selectionQ37155717
Neuregulins and cancer.Q37179990
DNA amplifications in breast cancer: genotypic-phenotypic correlationsQ37763102
Epistatic interactions and drug responseQ38150749
Biomarkers of drugs targeting HER-family signalling in cancer.Q38150774
The genomic profile of HER2-amplified breast cancers: the influence of ER statusQ38360582
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugsQ39584693
Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancerQ39945589
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migrationQ40203753
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomasQ40205335
Comprehensive profiling of 8p11-12 amplification in breast cancerQ40335646
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingQ43118556
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significanceQ44838384
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P304page(s)107
P577publication date2015-05-22
P1433published inGenome BiologyQ5533480
P1476titleIntra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
P478volume16